A new trading day began on Friday, with Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock price up 27.72% from the previous day of trading, before settling in for the closing price of $4.51. RXRX’s price has ranged from $3.79 to $12.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 112.62% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 5.03%. With a float of $305.89 million, this company’s outstanding shares have now reached $389.55 million.
In terms of profitability, gross margin is 10.66%, operating margin of -814.58%, and the pretax margin is -790.4%.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 23.91%, while institutional ownership is 60.20%. The most recent insider transaction that took place on Mar 27 ’25, was worth 836,987. In this transaction Chief Executive Officer of this company sold 138,574 shares at a rate of $6.04, taking the stock ownership to the 1,117,450 shares. Before that another transaction happened on Mar 27 ’25, when Company’s Officer proposed sale 138,574 for $6.04, making the entire transaction worth $836,987.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 5.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.81% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Here are Recursion Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 39.96 million. That was better than the volume of 24.31 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 56.61%. Additionally, its Average True Range was 0.68.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 22.99%, which indicates a significant decrease from 66.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 152.93% in the past 14 days, which was higher than the 112.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.89, while its 200-day Moving Average is $6.96. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $6.22. Second resistance stands at $6.68. The third major resistance level sits at $7.36. If the price goes on to break the first support level at $5.08, it is likely to go to the next support level at $4.40. Assuming the price breaks the second support level, the third support level stands at $3.94.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
With a market capitalization of 2.32 billion, the company has a total of 401,991K Shares Outstanding. Currently, annual sales are 58,840 K while annual income is -463,660 K. The company’s previous quarter sales were 4,550 K while its latest quarter income was -178,910 K.
